Editas Medicine, Inc. , a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases.
52W Range
52ndpctl
Volume
1.36×avg
Market Cap
484.94MUSD
P/E Ratio
-4.2TTM
Div Yield
-ann
Loading chart data...
Current StateState loading
Editas Medicine, Inc.
EDITNASDAQ·USD·Closed
Editas Medicine, Inc.
EDITNASDAQ·USD·Closed
$3.16
−4.24%
$3.16
−$0.14 (4.24%)
52W Range
52ndpctl
Volume
1.36×avg
Mkt Cap
484.94MUSD
P/E
-4.2TTM
Div Yield
–ann
EDIT: Editas Medicine, Inc. Stock Analysis | finqOS
